The CVS Health Corp (CVS) share price is expected to increase by 9.38% over the next year. This is based on calculating the average 12-month share price estimate provided by 24 stock analysts who have covered CVS. Price targets range from $59 at the low end to $91.12 at the high end. The current analyst consensus for CVS is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
CVS Health Corp has a total of 24 Wall St Analyst ratings. There are 15 buy ratings, 9 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that CVS Health Corp will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of CVS.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Stephen Baxter Wells Fargo | Equal-Weight | $60 | Maintains | Nov 4, 2024 |
Ann Hynes Mizuho | Outperform | $66 | Maintains | Oct 24, 2024 |
Andrew Mok Barclays | Overweight | $75 | Maintains | Oct 23, 2024 |
David Macdonald Truist Securities | Buy | $76 | Maintains | Oct 11, 2024 |
Andrew Mok Barclays | Overweight | $82 | Upgrade | Oct 10, 2024 |
Elizabeth Anderson Evercore ISI Group | Outperform | $75 | Maintains | Oct 8, 2024 |
Charles Ryhee TD Cowen | Buy | $85 | Upgrade | Oct 4, 2024 |
Sarah James Cantor Fitzgerald | Neutral | $62 | Reiterates | Oct 1, 2024 |
Sarah James Cantor Fitzgerald | Neutral | $62 | Reiterates | Sep 16, 2024 |
Sarah James Cantor Fitzgerald | Neutral | $62 | Reiterates | Sep 10, 2024 |
Ben Hendrix RBC Capital | Outperform | $68 | Reiterates | Sep 4, 2024 |
Sarah James Cantor Fitzgerald | Neutral | $62 | Reiterates | Aug 19, 2024 |
Stephen Baxter Wells Fargo | Equal-Weight | $61 | Maintains | Aug 12, 2024 |
George Hill Deutsche Bank | Hold | $63 | Maintains | Aug 9, 2024 |
Elizabeth Anderson Evercore ISI Group | Outperform | $62 | Maintains | Aug 8, 2024 |
Andrew Mok Barclays | Equal-Weight | $63 | Maintains | Aug 8, 2024 |
Sarah James Cantor Fitzgerald | Neutral | $62 | Maintains | Aug 8, 2024 |
Sarah James Cantor Fitzgerald | Neutral | $58 | Reiterates | Jul 23, 2024 |
Sarah James Cantor Fitzgerald | Neutral | $58 | Reiterates | Jun 12, 2024 |
Lisa Gill JP Morgan | Overweight | $86 | Maintains | May 30, 2024 |
When did it IPO
1984
Staff Count
219,000
Country
United States
Sector/Industry
Healthcare/Healthcare Plans
CEO
Ms. Karen Sue Lynch
Market Cap
$68.75B
In 2023, CVS generated $357.78B in revenue, which was a increase of 10.95% from the previous year. This can be seen as a signal that CVS's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Summary - CVS's stock increased following higher-than-expected revenue, although profits fell short due to a significant charge related to premium deficiency reserves.
Why It Matters - CVS's revenue beat expectations, indicating strong demand, but profit miss due to reserves may signal future challenges. This mixed performance affects investor confidence and stock valuation.
Summary - CVS Health's Q3 results were mixed due to rising medical costs impacting profits. The company has not provided a formal outlook due to ongoing elevated costs.
Why It Matters - CVS Health's mixed results and lack of guidance signal potential ongoing financial challenges, impacting investor confidence and stock performance due to rising medical costs.
Summary - CVS has announced new developments, as reported by CNBC's Bertha Coombs. Further details on the impact of these changes on the companyโs performance may be relevant for investors.
Why It Matters - CVS news can impact stock performance, business strategy, and competitive positioning in the healthcare sector, influencing investor sentiment and market movements.
Summary - CVS Health shares rose after the company reported better-than-expected results and CEO David Joyner announced leadership changes to improve performance.
Why It Matters - CVS's strong earnings and leadership changes signal potential turnaround strategies, boosting investor confidence and suggesting improved future performance.
Summary - U.S. stocks rose mid-session Wednesday, with the Nasdaq Composite up over 2%.
Why It Matters - Rising U.S. stock prices, particularly a 2% gain in the Nasdaq, indicate investor optimism and potential market momentum, which can drive further investment and influence trading strategies.
Summary - CVS Health appointed Steve Nelson, ex-UnitedHealth head, to lead Aetna amid rising medical costs, which led to a preannounced earnings miss for the third quarter.
Why It Matters - Steve Nelson's appointment at Aetna signals a strategic shift to address rising medical costs, impacting CVS's profitability and investor confidence following a recent earnings miss.